Ultrapure hyaluronic acid and the use thereof

• US 4,141,973 A
• Filed: 10/25/1977
• Issued: 02/27/1979
• Est. Priority Date: 10/17/1975
• Status: Expired due to Term

• Current Assignee: Biotrics Incorporated
• Original Assignee: Biotrics Incorporated
• Inventors: Balazs, Endre A.
• Primary Examiner(s): Meyers, Albert T.
• Assistant Examiner(s): Robinson, D. W.
• Application Number:
  US05/844,833
• Time in Patent Office: 490 Days
• Field of Search: 424/180, 260/209 R, 260/705
• US Class Current: 514/54
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Abstract

An ultra-pure, high molecular weight hyaluronic acid fraction which is characterized by the absence of significant cellular infiltration of the vitreous and anterior chamber, absence of significant flare in the aqueous humor, absence of significant haze or flare in the vitreous and absence of pathological changes to the cornea, lens, iris, retina, and choroid of the owl monkey eye when one milliliter of a 1% solution of the sodium salt thereof dissolved in physiological buffer is implanted in the vitreous replacing about one-half the existing liquid vitreous. This material is obtained from animal tissue containing hyaluronic acid by a process which comprises removing the blood from animal tissue containing hyaluronic acid, extracting hyaluronic acid therefrom, deproteinizing the hyaluronic acid extract, and removing any unidentified inflammation causing agents persent therein by treating the deproteinized hyaluronic acid extract at a pH of 6.0 - 7.0 with a volume of chloroform at least about equal to that of the deproteinized extract, to form a two-phase mixture which is then stirred, sufficiently to ensure intimate contact between said two phases, at about 15° - 40° C., followed by separating out and discarding the chloroform phase.

Claims

1. A sterile, pyrogen-free, protein-free, non-antigenic, hyaluronic acid fraction having an average molecular weight of at least about 750,000, a protein content of less than 0.5% by weight, ultraviolet light absorbance of a 1% solution of the sodium salt thereof of less than 3.0 at 257 nanometers wavelength and less than 2.0 at 280 nanometers wavelength, a kinematic viscosity of a 1% solution of the sodium salt thereof in physiological buffer of greater than about 1000 centistokes and a molar optical rotation of a 0.1-0.2% solution of the sodium salt thereof in physiological buffer of less than -11 = 10³ degree -- cm² /mole (of disaccharide) measured at 220 nonometers;

and which is characterized by infiltration by no more than about 200 white blood cells per mm³ of aqueous humor of the owl monkey eye when one milliliter of a 1% solution of the sodium salt of said fraction dissolved in physiological buffer is implanted in the vitreous replacing about one-half the existing liquid vitreous.

2. A fraction according to claim 1, wherein the molecular weight is at least about 1,200,000 and the kinematic viscosity is greater than about 10,000 centistokes.

3. The sodium salt of the hyaluronic acid fraction according to claim 1.

4. A method of improving pathological joint function in an animal by relieving pain, reducing inflammation and effecting the healing of an intraarticular wound associated therewith, said method comprising introducing by injection into an affected joint, an amount of hyaluronic acid according to claim 1, sufficient to increase the normal hyaluronic acid concentration in said joint by at least 5 times.

5. A method of enhancing normal joint and tendon function in an animal by lubricating said joint or tendon against excess stress during movement, said method comprising introducing into the synovial space associated with said joint or tendon an amount of the hyaluronic acid according to claim 1 sufficient to increase the normal hyaluronic concentration in said synovial space by at least 5 times.

6. A method according to claim 5, wherein the concentration is increased by a factor of 5 to 50 times.

7. A method according to claim 5, wherein said animal is a racing animal.

8. A method of preventing post-operative adhesion which may occur between healing tissues during the normal healing process, said method comprising introducing into a surgical site, either during surgery or post-operatively, an amount of the hyaluronic acid according to claim 1 sufficient to establish and maintain at the surgical site a hyaluronic acid concentration of at least about 1% for a period of about 24 hours post-operatively.

9. A method of separating healing tissues and maintaining said separation during the normal healing process after surgery, said method comprising introducing into a surgical site, either during surgery or post-operatively, an amount of the hyaluronic acid according to claim 1 sufficient to establish and maintain at the surgical site a hyaluronic acid concentration of at least about 1% for a period of about 24 hours post-operatively.

10. A method of protecting a layer of tissue during surgery on an adjacent layer of tissue, said method comprising introducing into the surgical site an amount of the hyaluronic acid according to claim 1 sufficient to prevent dislocation and movement of said tissue by providing a viscoelastic medium at the surgical site during said surgery.

11. A composition comprising the fraction according to claim 1 dissolved in a sterile physiological buffer solution containing NaCl, Na₂ HOP₄.7H₂ O and NaH₂ PO₄.H₂ O in pyrogen-free double distilled water.